Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NovaBay Pharmaceuticals Inc (NBY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NBY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.85
1 Year Target Price $0.85
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.87% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.85M USD | Price to earnings Ratio 0.5 | 1Y Target Price 0.85 |
Price to earnings Ratio 0.5 | 1Y Target Price 0.85 | ||
Volume (30-day avg) 1 | Beta 0.54 | 52 Weeks Range 0.30 - 2.93 | Updated Date 10/17/2025 |
52 Weeks Range 0.30 - 2.93 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 33.98% | Operating Margin (TTM) -57.85% |
Management Effectiveness
Return on Assets (TTM) -65.27% | Return on Equity (TTM) -413.78% |
Valuation
Trailing PE 0.5 | Forward PE - | Enterprise Value 4892795 | Price to Sales(TTM) 0.7 |
Enterprise Value 4892795 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 0.5 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 6010749 | Shares Floating 4828727 |
Shares Outstanding 6010749 | Shares Floating 4828727 | ||
Percent Insiders 0.09 | Percent Institutions 20.63 |
Upturn AI SWOT
NovaBay Pharmaceuticals Inc
Company Overview
History and Background
NovaBay Pharmaceuticals Inc. was founded in 2000. It is a biopharmaceutical company focusing on developing and commercializing anti-infective products for the eyecare market. The company has evolved from focusing on a broader range of anti-infective applications to a more specialized focus on ophthalmic solutions.
Core Business Areas
- Avenova: Avenova is a proprietary, prescription-strength lid and lash cleanser. It's the company's primary revenue driver and is used to manage conditions like blepharitis and dry eye.
- NeutroPhase: NeutroPhase is a wound irrigation solution intended for use in hospitals and surgical settings. Its contribution to revenue is smaller than Avenova.
Leadership and Structure
NovaBay Pharmaceuticals Inc. is led by a management team including a CEO, CFO, and various vice presidents overseeing different departments like R&D, commercial operations, and medical affairs. The company has a Board of Directors responsible for governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Avenova: Avenova is a prescription-strength antimicrobial lid and lash solution containing pure hypochlorous acid (HOCl). Competitors include OTC lid scrubs, baby shampoo, and other prescription products, but Avenova has a unique delivery system and HOCl formulation. Avenova generated the vast majority of NovaBay's revenue. Precise market share data is not readily available but its competitive advantage is it is the only formulation with 0.01% Hypochlorous acid.
- NeutroPhase: NeutroPhase is a pure hypochlorous acid solution used for wound irrigation. Competitors include other wound care solutions containing different active ingredients like iodine and silver. Revenue from NeutroPhase is significantly less than Avenova.
Market Dynamics
Industry Overview
The ophthalmic market is growing due to aging populations, increased prevalence of eye conditions like dry eye and blepharitis, and growing awareness of eye health. The wound care market is also substantial, driven by the increasing incidence of chronic wounds, surgical procedures, and diabetes.
Positioning
NovaBay Pharmaceuticals Inc. is positioned as a specialty pharmaceutical company focused on eye care with its Avenova product. The company's competitive advantage lies in its proprietary HOCl formulation and delivery system. They also participate in the wound-care market, however it is not the primary driver of growth for the company.
Total Addressable Market (TAM)
The total addressable market for dry eye and blepharitis treatments is estimated to be in the billions of dollars globally. NovaBay is positioned to capture a portion of this market through Avenova. The TAM for wound care is also significant and they hope to capture a small portion of the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary HOCl technology
- Established brand name (Avenova)
- Prescription-strength product
- Specialized focus on ophthalmic market
Weaknesses
- Limited product portfolio
- Reliance on a single key product (Avenova)
- Small market capitalization
- Fluctuating financials
Opportunities
- Expanding Avenova sales through partnerships
- Developing new ophthalmic products
- Acquiring complementary businesses
- Geographic expansion
Threats
- Competition from larger pharmaceutical companies
- Generic entry of HOCl products
- Regulatory changes
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- ALGN
- OCUL
- IIVI
Competitive Landscape
NovaBay is a smaller player compared to competitors. Avenova has a unique selling proposition, but larger companies have more resources for marketing and R&D.
Growth Trajectory and Initiatives
Historical Growth: NovaBay has experienced fluctuating revenue growth, dependent on Avenova sales and marketing efforts.
Future Projections: Future growth depends on expanding the market reach of Avenova and developing new products. Analyst estimates can vary, so please see them directly.
Recent Initiatives: Recent initiatives include partnerships to expand Avenova sales and efforts to increase awareness of HOCl technology.
Summary
NovaBay Pharmaceuticals Inc. is a small biopharmaceutical company with a focus on eye care, driven primarily by Avenova sales. While it has a proprietary technology and a recognizable brand, its reliance on a single product and small market capitalization pose challenges. The company needs to focus on expanding its product portfolio and securing more partnerships to mitigate risks and achieve sustained growth. Competition is high and could hinder the company's growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Third-party financial data providers
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimated revenues and publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NovaBay Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2007-10-26 | CEO & Director Mr. David Elliot Lazar | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://novabay.com |
Full time employees 13 | Website https://novabay.com | ||
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.